Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2011

01-12-2011 | Research Article

Evaluation of multiple serum markers in advanced melanoma

Authors: Angel Díaz-Lagares, Estíbaliz Alegre, Ainhoa Arroyo, María González-Cao, Maria E. Zudaire, Santiago Viteri, Salvador Martín-Algarra, Alvaro González

Published in: Tumor Biology | Issue 6/2011

Login to get access

Abstract

The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.
Literature
1.
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46:270–83PubMedCrossRef
2.
Brochez L, Naeyaert J-M (2000) Serological markers for melanoma. British J Dermatol 143:256–68CrossRef
3.
Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G (2010) Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v194–7PubMedCrossRef
4.
Jennings L, Murphy GM (2009) Predicting outcome in melanoma: where are we now? Br J Dermatol 161:496–503PubMedCrossRef
5.
Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 19:3635–48PubMed
6.
Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C (2010) Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 163:238–56PubMedCrossRef
7.
Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17:2417–25PubMedCrossRef
8.
Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558–63PubMedCrossRef
9.
Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–53PubMed
10.
Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL (1998) Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 187:191–7PubMedCrossRef
11.
Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130–9PubMedCrossRef
12.
Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA (1997) Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 137:381–5PubMedCrossRef
13.
Gogas H, Eggermont AMM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R (2009) Biomarkers in melanoma. Ann Oncol 20:vi8–13PubMedCrossRef
14.
Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37:512–8PubMedCrossRef
15.
Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35:433–44PubMedCrossRef
16.
Bosserhoff AK, Hein Rd, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271:490–5PubMedCrossRef
17.
Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, A New prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194–202PubMedCrossRef
18.
Krause S, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis J, Andreesen R (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukocyte Biol 60:540–5PubMed
19.
Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M (2001) Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 20:192–6PubMedCrossRef
20.
Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076–83PubMedCrossRef
21.
Johansen JS, Bojesen SE, Tybjaerg-Hansen A, Mylin AK, Price PA, Nordestgaard BG (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 56:1580–91PubMedCrossRef
22.
Johansen JS, Jensen BV, Roslind A, Price PA (2007) Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets 11:219–34PubMedCrossRef
23.
Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891–6PubMed
24.
Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, Vilella R, Conill C, Sanchez M, Malvehy J, Puig S (2007) Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 27:595–9PubMed
25.
Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Bricon TL (2007) Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43:816–21PubMedCrossRef
26.
Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A (2008) Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31:380–4PubMedCrossRef
27.
Dummer R, Panizzon R, Bloch PH, Burg G (2005) Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 210:39–44PubMedCrossRef
28.
Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6:S9–14PubMedCrossRef
29.
Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastasis compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311–6PubMed
30.
Garbe C, Leiter U, Ellwanger U, Blaheta H-J, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97:1737–45PubMedCrossRef
31.
Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL (2007) A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Investigation 25:285–93PubMedCrossRef
32.
Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–44PubMedCrossRef
33.
Auge JM, Molina R, Filella X, Bosch E, Cao MG, Puig S, Malvehy J, Castel T, Ballesta AM (2005) S-100B and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 25:1779–82PubMed
34.
Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMed
35.
Siekmann L, Bonora R, Burtis CA, Ceriotti F, Clerc-Renaud P, Ferard G, Ferrero CA, Forest JC, Franck PF, Gella FJ, Hoelzel W, Jorgensen PJ, Kanno T, Kessner A, Klauke R, Kristiansen N, Lessinger JM, Linsinger TP, Misaki H, Mueller MM, Panteghini M, Pauwels J, Schiele F, Schimmel HG, Vialle A, Weidemann G, Schumann G (2002) IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate dehydrogenase, alanine aminotransferase and creatine kinase accord. Clin Chem Lab Med 40:739–45PubMedCrossRef
36.
Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ (2009) S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 16:3455–62PubMedCrossRef
37.
Hofmann MA, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I, Voit C, Trefzer U (2009) Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 19:17–23PubMedCrossRef
38.
Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27:38–44PubMedCrossRef
Metadata
Title
Evaluation of multiple serum markers in advanced melanoma
Authors
Angel Díaz-Lagares
Estíbaliz Alegre
Ainhoa Arroyo
María González-Cao
Maria E. Zudaire
Santiago Viteri
Salvador Martín-Algarra
Alvaro González
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0218-x

Other articles of this Issue 6/2011

Tumor Biology 6/2011 Go to the issue

Research Article

NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy

Research Article

The expression of p33ING1, p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer

Review

PDGF: the nuts and bolts of signalling toolbox

Research Article

Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells

Research Article

Evaluation of the phenotype pattern of macrophages isolated from malignant and non-malignant pleural effusions

Research Article

SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits